Accessibility Menu
Telix Pharmaceuticals logo

Telix Pharmaceuticals(NASDAQ) TLX

Market Cap$4.22BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-18%
5 YearN/A
1 Year+13%
1 Month+14%
$11.33
-8.82%
-1.09Today
Telix Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 12.422026-08-20
Telix Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.73%USD 12.332026-08-13
1 month+13.74%USD 10.922026-07-21
3 month+31.15%USD 9.472026-05-22
Year to date+65.82%USD 7.492025-12-31
1 year+13.22%USD 10.972025-08-20
Since inception-18.02%USD 15.152024-11-14

Telix Pharmaceuticals Financials at a Glance

Market Cap

$4.22BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.00B

Net Income (TTM)

A$39.18M

EPS (TTM)

-$0.02

P/E Ratio

-588.63

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$11.33

Volume

182,871.471

Open

$11.34

Previous Close

$12.42

Daily Range

$11.19 - $11.39

52-Week Range

$6.28 - $12.60

Estimated Earnings Date

Feb 19, 2027

TLX News

Adaptimmunenew

1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth

James HalleyFeb 26, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, with a strong emphasis on innovative cancer treatments.

Products and Services
  • TLX591: A lutetium-labeled radio antibody-drug conjugate for advanced prostate cancer
  • TLX250: An rADC targeting advanced metastatic kidney cancer
  • Illuccix and Gozellix: Products for prostate cancer treatment
Growth Outlook
  • Recent quarterly revenue reached AUD 620 million, indicating strong market demand
  • Ongoing Phase 3 trials for TLX591 and TLX250 highlight significant development potential
  • Strategic collaborations with leading institutions enhance research capabilities
Financial Highlights
  • Trailing twelve-month revenue of AUD 2.4 billion reflects robust growth
  • Operating income margin improved to 1.6% in the latest quarter
  • Cash and cash equivalents stood at AUD 212 million, ensuring liquidity
Telix Pharmaceuticals Limited is positioned in the biotechnology sector, focusing on innovative solutions for cancer treatment. The company's lead products, including TLX591 and TLX250, are in advanced clinical trials, showcasing its commitment to addressing unmet medical needs. The recent financial performance indicates a strong revenue trajectory, supported by strategic collaborations and a solid cash position. Investors may find Telix's focus on precision medicine and its expanding product pipeline appealing as the company continues to advance its clinical programs.
AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,184

CEO

Christian P. Behrenbruch, PhD, EMBA

Website

www.telixpharma.com

Headquarters

North Melbourne, VIC 3051, AU

TLX Financials

Key Financial Metrics (TTM)

Gross Margin

52.16%

Operating Margin

-0.73%

Net Income Margin

3.60%

Return on Equity

7.11%

Return on Capital

2.02%

Return on Assets

2.40%

Earnings Yield

-0.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.22BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

339.78M

Volume

182.87K

Avg. Volume

161.42K

Financials (TTM)

Gross Profit

A$1.13B

Operating Income

A$107.74M

EBITDA

A$160.90M

Operating Cash Flow

A$13.35M

Capital Expenditure

-A$64.41M

Free Cash Flow

-A$51.07M

Cash & ST Invst.

A$212.53M

Total Debt

A$699.77M

Telix Pharmaceuticals Performance Analysis

Telix Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 110,983,5751846.6%
20232023-12-31AUD 333,573,719200.6%
20242024-12-31AUD 516,602,59754.9%
20252025-12-31AUD 804,636,84755.8%
Telix Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-32.9%
Q42024-12-31214.5%
Q22025-06-30-0.2%
Q42025-12-314.6%
Telix Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.238.5%
20232023-12-31AUD 0.01N/A
20242024-12-31AUD 0.10791.6%
20252025-12-31AUD -0.02N/A
Telix Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-44.8%
Q42024-12-31230.3%
Q22025-06-30-109.4%
Q42025-12-31-107.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

A$620.44M

+120.2%

Gross Profit

A$327.42M

+46.2%

Gross Margin

52.77%

N/A

Market Cap

$4.22BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.66M

N/A

Employees

1,152

N/A

Net Income

-A$7.25M

-137.1%

EBITDA

A$28.92M

+25.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

A$212.53M

+72.5%

Total Debt

A$699.77M

+3911.3%

Accounts Receivable

A$207.29M

+220.0%

Inventory

A$55.55M

+220.9%

Long Term Debt

A$671.82M

+4129.0%

Short Term Debt

A$27.95M

+1692.9%

Return on Assets

2.40%

N/A

Return on Invested Capital

-0.59%

N/A

Free Cash Flow

-A$92.60M

-2441.3%

Operating Cash Flow

-A$52.55M

-594.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CELCCelcuity Inc.
$95.04+4.94%
DYNDyne Therapeutics, Inc.
$26.41+1.64%
ACADACADIA Pharmaceuticals Inc.
$29.33+1.00%
SLNOSoleno Therapeutics, Inc.
$53.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$43.67+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.42+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.71+0.09%
MARAMara Holdings
$11.18+0.00%

Questions About TLX

What is the current price of Telix Pharmaceuticals?

Telix Pharmaceuticals is trading at $11.33 per share.

What is the 52-week range for Telix Pharmaceuticals?

Over the past 52 weeks, Telix Pharmaceuticals has traded between $6.28 and $12.60.

How much debt does Telix Pharmaceuticals have?

As of the most recent reporting period, Telix Pharmaceuticals reported total debt of A$467.11M.

How much cash does Telix Pharmaceuticals have on hand?

Telix Pharmaceuticals reported A$141.87M in cash and cash equivalents in its most recent financial results.

What is Telix Pharmaceuticals’s dividend yield?

Telix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services